Kleder (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers degradation of transcription factors that support malignant cell survival, reduces angiogenesis, and modulates immune cells, leading to apoptosis of cancerous plasma cells and enhanced anti‑tumor immunity.

The dosing of Kleder is individualized and must be determined by a qualified prescriber based on the specific indication, patient characteristics, and clinical response. Physicians adjust the dose according to treatment guidelines and laboratory monitoring.

Lenalidomide is classified as Pregnancy Category X. It is contraindicated in pregnancy because of a high risk of fetal harm. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while taking the medication.

To order Kleder, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory imide drug. Lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy, and has stronger anti‑angiogenic and immune‑activating effects. Both drugs share teratogenic risk, so strict contraception is required.

Kleder should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat. Keep it out of reach of children and do not use after the expiry date.

Kleder is taken orally, usually with or without food, as directed by the prescribing physician. The tablets should be swallowed whole with a full glass of water and not crushed or chewed unless specifically instructed.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, and potential liver toxicity indicated by elevated liver enzymes. Patients should be monitored regularly for these complications.

Kleder is contraindicated in pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with uncontrolled active infections. Caution is also advised for those with severe renal or hepatic impairment.